TickerTalks
Browse all tickers →
TickerTalks›$HALO
HAHALO

Halozyme Therapeutics, Inc.

Strong FundamentalsStrong FundamentalsRevenue growing 42% YoY at strong marginsStreet coverage with positive forward estimatesConsistent chatter on X (142/wk), no spike
$HALO·$12B·Biotechnology·Healthcare
$98.66-2.0%YTD+22.9%1Y+50.5%
Mentions · last 7 days
2026-08-08: 22 posts2026-08-09: 27 posts2026-08-10: 18 posts2026-08-11: 39 posts2026-08-12: 15 posts2026-08-13: 5 posts2026-08-14: 8 posts142+8%
Price updated 2d ago·X counts updated 2d ago
HAHALO
$HALOHalozyme Therapeutics, Inc.
$98.66-2.00%142 posts+8%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $HALO, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Proven numbersAcceleratingAI verdict · as of 2026-08-14

The move is getting stronger, with heavier trading behind it.

ENHANZE royalty business +48% Q2 + $1B buyback + Morgan Stanley $105 — best-in-class biotech economics compounding.

Halozyme Therapeutics is the biotech behind ENHANZE, the subcutaneous drug-delivery platform pharma companies license to convert IV-infused drugs into at-home injections. Q2 posted a blowout print — revenue +48% and a $1B buyback — and the stock is up 15% on the news, near 52-week highs.

  • The Q2 growth is unusual for a mature royalty-and-milestone business: revenue of $481M beat the $402M consensus with adjusted EPS at $1.90 versus $1.48 — a magnitude of beat that essentially resets the market's understanding of the ENHANZE royalty ramp.
  • The core economics are best-in-class biotech: 77% gross margin and 57% operating margin (per bundle) reflect the pure-royalty business model — the type of profitability profile that supports the multiple even without a fresh partner or new indication.
  • The $1B buyback is a load-bearing capital-return signal: authorization of that magnitude for a $12B market cap is roughly 8-9% of shares outstanding — a specific commitment level that says management sees the current price as attractive against forward cash-flow generation.
  • The Morgan Stanley PT raise to $105 from $93 keeps the multiple defensible: the sell-side is now aligned that the ENHANZE partner-drug pipeline (across Roche, J&J, and others) supports continued royalty ramp — the reason bulls are willing to hold at 26x trailing earnings.

Coming into Nov 2 earnings, the tape needs continued partner-drug royalty acceleration, ENHANZE partnership expansion (any new pharma license announcement), and buyback pace confirmation. A clean beat plus any new partner deal extends the trend past $105; a slip in royalty-partner performance or absence of pipeline updates is what would compress the just-raised multiple. The Warden Protocol HALO crypto chatter is unrelated to the equity.

Agrees with X sentimentAgree with the fully-bullish read — the Q2 beat magnitude, the $1B buyback, and the Morgan Stanley PT raise are all sized signals aligned with the ENHANZE compounding thesis. The Warden Protocol HALO crypto chatter is a separate asset with no bearing on the equity.

What to watch: Nov 2 Q3 earnings — continued partner-drug royalty acceleration, any new ENHANZE partnership announcement, and buyback pace confirmation. A slip in royalty-partner performance or absence of pipeline updates compresses the just-raised multiple.

On the calendar: 2026-11-02 — Q3 earnings

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Bullish sentiment33 posts analyzed · as of 2026-08-14

HALO ticker splits between Halozyme (equity) and Warden Protocol crypto. On the equity side, Halozyme was cited alongside Natera as an IBD 50 stock surging on solid Q2 earnings tied to their SC drug conversion tech. On the crypto side, Warden Protocol's $HALO launched with no presale/insider allocation, 10-year LP lock, permissionless AI inference marketplace, already at $45M+ mcap with $900K+ liquidity mentioned by Base's weekly recap. 50k HALO incentives live for volume and net buying. Both threads bullish, no bear voice.

Read the AI verdict + X sentiment for $HALO

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Proprietary ENHANZE drug delivery platform converts IV biologics into subcutaneous injections; licensed to 15+ pharma partners including J&J and Roche.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $HALO.

Biotechnology · Healthcare

No material change from last week — ADA conference oral formulation competition is bifurcating biotech multiples between GLP-1 platform holders and precision oncology innovators.

What this means for $HALO

Partial — Proprietary ENHANZE drug delivery platform converts IV biologics into subcutaneous injections; licensed to 15+ pharma partners including J&J and Roche; partial earnings exposure to biotechnology demand dynamics through its product portfolio.

Top industry ETF

$IBBiShares Biotechnology ETF
+12.1%YTD
+44.4%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
26.4How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
23.6%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
57.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
7.3%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
6.1Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
126%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
76.9%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
9.8Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 6, 2026$2.28$1.79+27.4%
Q1 2026May 11, 2026$1.60$1.55+3.2%
Q4 2025Feb 17, 2026$-0.24$2.15-111.2%
Q3 2025Nov 3, 2025$1.72$1.63+5.5%
Next earningsMon, Nov 2·consensus EPS $2.11

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$376.7M+42.2%71.1%49.0%$1.27$176.3M
Q4 FY25$451.8M+51.6%77.4%56.3%$-1.20$217.6M
Q3 FY25$354.3M+22.1%79.4%61.5%$1.49$175.6M
Q2 FY25$325.7M+40.8%80.3%62.2%$1.36$98.1M

Forward consensus

5-year forecast · up to 7 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$1.8B$1.7B – $1.8B$7.94$7.82 – $8.027
FY27$2.0B$1.9B – $2.1B$9.97$9.75 – $10.246
FY28$2.2B$2.1B – $2.2B$11.12$11.09 – $11.145
FY29$2.0B$2.0B – $2.1B$10.08$9.80 – $10.392
FY30$1.8B$1.7B – $1.8B$8.87$8.63 – $9.142

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.8×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.86%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+24.0%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+38.5%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMid float · 117.3M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today1.4% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.855-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellAug 10Bernadette ConnaughtonDirector1.6K sh$167KSellJul 8Helen TorleyCEO1.9K sh$153KSellJul 1Bernadette ConnaughtonDirector1.6K sh$125KSellJun 29Mahesh KrishnanDirector7.3K sh$548KSellJun 3Helen TorleyCEO10.0K sh$691KSellJun 2Helen TorleyCEO20.0K sh$1.3MSellJun 1Helen TorleyCEO20.0K sh$1.4MSellJun 1Bernadette ConnaughtonDirector1.6K sh$108KSellMay 13Helen TorleyCEO10.0K sh$692KSellMay 12Helen TorleyCEO20.0K sh$1.4M
1–10 of 11
+ 20 other (10 exempts · 8 awards · 2 inkinds) in window

See when $HALO insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KOfficer or director changeJul 28-K — Item 5.02: Officer or director change
AI summary

Halozyme Therapeutics announced the departure of Cortney Caudill as SVP and COO on June 30, 2026, with no replacement named. Filing signed by CFO Darren Snellgrove. Administrative executive departure leaving the COO role vacant.

3New insider — initial holdingsJun 93
AI summary

Darren Snellgrove, SVP and CFO of Halozyme Therapeutics, filed a Form 3 initial beneficial ownership statement as of June 8, 2026. Administrative disclosure.

8-KShareholder voteMay 78-K — Item 5.07: Shareholder vote
AI summary

Halozyme's Annual Meeting on May 5, 2026 had 104.14M of 118.47M shares outstanding represented. Three proposals were voted on, including the election of two Class I directors to 3-year terms; detailed vote results are not visible in the excerpt. Annual meeting results confirming director elections.

8-KOfficer or director changeApr 308-K — Item 5.02: Officer or director change
8-KCharter amendmentApr 248-K — Item 5.03: Charter amendment
3New insider — initial holdingsMar 233
8-KOfficer or director changeMar 128-K — Item 5.02: Officer or director change
+ 11 other (3 earnings 8-Ks · 2 10-Qs · 2 13Gs · 2 proxys) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Halozyme Therapeutics (HALO) is an Incredible Growth Stock: 3 Reasons Whyzacks.com·3d agoIs Halozyme Therapeutics (HALO) Stock Outpacing Its Medical Peers This Year?zacks.com·3d agoHalozyme's Q2 Earnings Beat Estimates, 2026 Outlook Raised, Stock Upzacks.com·9d agoHalozyme Therapeutics Q2 Earnings Call Highlightsmarketbeat.com·10d agoHalozyme Therapeutics, Inc. (HALO) Q2 2026 Earnings Call Transcriptseekingalpha.com·10d ago

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$ABCL$CAPR$ALLO$NWBO$TENX$AURA$SION$IBRX
Voices on X · top 12 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport